AI healthcare roundup: Eisai & TytoCare new Solutions
![](https://assets.bizclikmedia.net/138/10c31afbb72e093897d23bab240f8b6f:a1ea271d64cce3455596f1b72754daf6/tytocare.webp)
Eisai in Medidata AI clinical trials tie-up
Clinical trial specialist Medidata has announced that Eisai is the first customer to harness its recently launched AI-driven Medidata Clinical Data Studio.
Eisai, the US pharmaceutical subsidiary of Tokyo-based Eisai Co, will use the solution to gain control over its clinical data, to “enable the execution of scalable and complex clinical trials, and enhance patient experience”, the company says.
Utilising AI, Clinical Data Studio mitigates challenges posed by disparate data systems. It is powered by the Medidata Platform, which centrally manages all data sources, improving data reliability across the entire clinical trial ecosystem.
By delivering an AI-driven data management experience, we're enabling study teams to gain a more accurate understanding of the patient
The company says it offers up to 80% faster data review, “while providing a comprehensive view of patient data that can be concurrently reviewed, visualised and acted upon”.
“We’ve included Medidata’s Clinical Data Studio in our clinical trial management platform because of its ability to break down data silos and seamlessly integrate into our current software stack, while maintaining quality and integrity across all data sources,” said Shobha Dhadda, Chief Clinical Science & Operations Officer at Eisai.
She added: “It offers a suite of technology solutions capable of processing diverse clinical and patient data types provides increased efficiencies without sacrificing quality or needing additional resources.”
“Through Clinical Data Studio, Eisai is enabling healthcare stakeholders to overcome the complexities of modern clinical trials and foster collaboration on cleaner, more actionable data,” said Janet Butler, Medidata EVP & Global Head of Sales.
“By delivering a unified AI-driven data management and analytics experience, we are enabling study teams to identify potential data issues faster and gain a more accurate understanding of the patient.”
Virtual care specialist TytoCare unveils AI lung tool
Virtual-care company TytoCare has received FDA clearance for a new AI-powered diagnostic capability.
The company’s lung disease detection tool, Insights for Crackle Detection, is built on a database of lung sound recordings and driven by an AI-based algorithm.
It is designed to help clinicians detect lung crackles in adults and children over two years old that may need attention during a virtual clinic visit.
By identifying lung crackles in a virtual visit, healthcare providers can direct patients to the most appropriate follow-up treatment to manage their health.
“The integration of AI into our diagnostic tools significantly enhances clinician efficiency and speed to diagnosis,” said Dedi Gilad, CEO and Co-Founder of TytoCare. “With our new AI-powered crackle detection algorithm, which was trained using data validated by pulmonologists.”
The new feature will be available in September.